The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume
Open accessAbstract
Background The glutamate model of schizophrenia proposes that altered glutamatergic neurotransmission is fundamental to the development of the disorder. In addition, its potential to mediate neurotoxicity raises the possibility that glutamate dysfunction could underlie neuroanatomic changes in schizophrenia. Here we determine whether changes in brain glutamate are present in subjects at ultra high risk of developing psychosis and whether these changes are related to reductions in cortical gray matter volume.Methods Twenty-seven individuals with an at-risk mental state and a group of 27 healthy volunteers underwent proton magnetic resonance spectroscopy and volumetric proton magnetic resonance imaging using a 3-Tesla scanner. Glutamate and glutamine levels were measured in anterior cingulate, left hippocampus, and left thalamus. These measures were then related to cortical gray matter volume.Results At-risk mental state (ARMS) subjects had significantly lower levels of glutamate than control subjects in the thalamus (p < .05) but higher glutamine in the anterior cingulate (p < .05). Within the ARMS group, the level of thalamic glutamate was directly correlated with gray matter volume in the medial temporal cortex and insula (p < .01).Conclusions This study provides the first evidence that brain glutamate function is perturbed in people with prodromal signs of schizophrenia and that glutamatergic dysfunction is associated with a reduction in gray matter volume in brain regions thought to be critical to the pathogenesis of the disorder. These findings support the hypothesis that drugs affecting the glutamate system may be of benefit in the early stages of psychotic illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, diminished glutamate receptor activation, in particular of the NMDA-type of glutamate receptor, may be a possible underlying mechanism of reduced synaptic activity because NMDA-receptor antagonists produce the same symptoms as those seen in schizophrenia.17,18,25”
From Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies (2013) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
Provencher, S. W. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300604 · Cited by 3,659
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., John Suckling, A., Phillips, L., Yung, A. R., Bullmore, E. T., Brewer, W. J., Soulsby, B., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12323-9 · Cited by 1,309
Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & McGorry, P. D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00167-6 · Cited by 1,136
Bullmore, E. T., Suckling, J., Overmeyer, S., Rabe-Hesketh, S., Taylor, E., & Brammer, M. J. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.750253 · Cited by 1,088
Cited by
Sorted by citations
Items 201–231 of 231
Ricci, V., Martinotti, G., & Maina, G. (2026) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2025.100332 · Cited by 1
RetractedVues sur le cerveau en transition
McGuire, P. K. (2010) · L Encéphale · doi:10.1016/s0013-7006(10)70033-6 · Cited by 1
Singh, U., Das, B., Khanra, S., & Roy, C. (2024) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_621_23 · Cited by 1
Psychological Methods of Early Intervention in Emerging Psychosis
Müller, H., & Bechdolf, A. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440921 · Cited by 1
Capellán, R., Moreno, M., Orihuel, J., Roura‐Martínez, D., Ucha, M., Ambrosio, E., & Higuera‐Matas, A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/641761 · Cited by 1
Lopes, J. J., Dean, B., Carruthers, S. P., & Rossell, S. L. (2020) · doi:10.31234/osf.io/af8ns · Cited by 1
Maksimovic, M. (2015) · Työväentutkimus Vuosikirja
Bipolar disorder and cognitive functioning : a two-year naturalistic study
Arts, B. M. G. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20120511ba
Stone, J. M., Howes, O. D., Egerton, A., Kambeitz, J. P., Allen, P., Lythgoe, D. J., Tuura, R., McLean, M. A., Barker, G. J., & McGuire, P. K. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.039
de la Fuente‐Sandoval, C., & Graff‐Guerrero, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.203
Aoyama, N. (2011) · Scholarship@Western (Western University)
Structural and Functional MRI in the Prediction of Psychosis
Dwyer, D., & McGuire, P. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440916 · Cited by 1
Chapter 3 Brain Imaging in Early Stages of Psychosis: From the at Risk Mental State to First Episode
McGuire, P. K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7264-3_3
Sleep Dysfunction in Adolescents at High Risk for Psychosis
Avery, J. R. L. (2014) · CU Scholar (University of Colorado Boulder)
Lawford‐Smith, H. (2015)
Inhibition of Gamma Oscillations as a Neurophysiological Endophenotype of Schizophrenia
Radhu, N. (2015) · TSpace (University of Toronto)
Borgwardt, S., & Fusar‐Poli, P. (2012)
A 1H-MRS and Neurocognitive Analysis of Psychotic Symptoms in Stimulant Dependence
Lakusta, B. (2012) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3q04w
Wu, A. (2019) · TSpace (University of Toronto)
Chapitre 9. Imagerie dans les phases précoces de la schizophrénie
Krebs, M. (2015) · Dunod eBooks · doi:10.3917/dunod.krebs.2015.01.0143
Lahogue, C., & Pinault, D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.08.329912
Frissen, A. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161221af
Roalf, D. R., Moore, T. M., Stifelman, J., Pecsok, M. K., Atkins, A., Baller, E. B., Calkins, M. E., Biasi, M. D., Kohler, C. G., Mastracchio, C., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03705-1
Diazepam modulates anterior cingulate glutamate levels in people at clinical high-risk for psychosis
Kiemes, A., Livingston, N. R., Lukow, P. B., Knight, S., Jelen, L. A., Reilly, T. J., Dima, A., Nettis, M. A., Lythgoe, D. J., Casetta, C., et al. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf078
Molecular Neuroimaging, Pathophysiological Mechanisms, and Drug Discovery
McGuire, P. K. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0913-8_8
Marqueurs neurodéveloppementaux en psychiatrie : intérêt dans les troubles schizophréniques
Gay, O. (2016) · theses.fr (ABES) · doi:10.70675/b0e8f0f3ze67bz4340z9b3cz01b56b6184f0
Gee, A. L., Livingston, N. R., Kiemes, A., Knight, S., Lukow, P. B., Lythgoe, D. J., Vorontsova, N., Donocik, J. G., Davies, J., Rabiner, E. A., et al. (2026) · medRxiv · doi:10.64898/2026.04.08.26350385
Assessing In Vivo Neurodegeneration in Schizophrenia Using Magnetic Resonance
Théberge, J. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_4
Chen, J. (2014) · UNM’s Digital Repository (University of New Mexico)
Metadata
- Authors
- Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K.
- Affiliations
- University of London (GB)
- UCL Queen Square Institute of Neurology (GB)
- Corresponding author
- Stone, James M.
- ORCID
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 66
- Issue
- 6
- Pages
- 533-539
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1994737820
- Cited by
- 231
- References
- 45
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 7 · 2022: 3 · 2021: 13 · 2020: 16 · 2019: 17 · 2018: 11 · 2017: 11 · 2016: 10 · 2015: 20 · 2014: 21 · 2013: 20 · 2012: 21
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- glutamate dysfunction, glutamatergic neurotransmission, schizophrenia, clinical high risk for psychosis, prodromal psychosis, gray matter volume, glutamine, thalamus, anterior cingulate cortex, hippocampus, insula, neurotoxicity, 1H NMR
- MeSH terms
- Adult, Mental Disorders, Brain Mapping, Female, Glutamine, Humans, Magnetic Resonance Imaging, Male, Magnetic Resonance Spectroscopy, Protons, Psychiatric Status Rating Scales, Risk, Temporal Lobe, Thalamus, Glutamic Acid, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
